A clinical trial is a significant accomplishment for Medicortex
“Collecting and testing human samples in a clinical trial is a significant accomplishment for Medicortex, and represents a meaningful step forward in the development of a fast inexpensive diagnostic kit for head injury,” said Dr. Adrian Harel, Chairman and Chief Executive Officer of Medicortex Finland. “Brain injury is a devastating condition with mortality if not diagnosed. The opportunity to develop the first portable non-invasive kit for head injury and concussion to help the patients and families that so desperately need it is remarkable.”
In this clinical trial we intend to collect body fluid samples of 12 patients who have sustained a head injury, and analyze for the existence of a biomarker between the patients and healthy control subjects. Based on our earlier laboratory animal tests we can expect promising result from the study.
[https://clinicaltrials.gov/ct2/show/NCT02836951?term=medicortex&rank=1]
Dr. Marten Kvist, “We are excited to begin a clinical test, confirming the presence of this unique biomarker, it will be further developed into a diagnostic aid for first responders and paramedics, it will help prioritize evacuation and reframe from administration of contraindicated medications”
Medicortex is working towards the identification of a Traumatic Brain Injury (TBI) biomarker and incorporating it into a quick and reliable diagnostic kit that can be easily used by the first responders and healthcare professionals, and also by people with no medical profession.
This clinical trial is supported and funded in part by Tekes (the Finnish Funding Agency for Innovation)
About Medicortex
Medicortex Finland Oy is a biotechnology company dedicated to developing diagnostics and treatments for acute neurodegenerative conditions, including brain injury and concussion. One of the company's missions is to identify a new biomarker in order to reliably assess the severity and extent of brain injury. Medicortex was founded by Dr. Adrian Harel in Turku, Finland, in 2014 and it operates as a privately owned company. Dr. Harel has a track record in the business management and leadership of early-stage biotechnology companies.
Forward-Looking Statements
This press release contains statements that are “forward-looking statements” that are based upon management’s current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated herein.
Contacts
Dr. Adrian Harel - CEO
Medicortex Finland Oy
PharmaCity
Itäinen Pitkäkatu 4 B,
FI-20520 Turku, Finland
Tel. +358 (0) 400 488 817
Fax. +358 (0) 2 251 0100
adrian.harel@medicortex.fi
Links
About Medicortex Finland Oyj
Medicortex Finland OyjMedicortex Finland Oyj (www.medicortex.fi) on tutkimuslähtöinen lääkealan yritys, joka kehittää uudenlaista diagnostista menetelmää perustuen biomerkkiaineisiin.
Subscribe to releases from Medicortex Finland Oyj
Subscribe to all the latest releases from Medicortex Finland Oyj by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Medicortex Finland Oyj
A European patent granted for Medicortex11.12.2025 17:00:00 EET | Press release
The European Patent Office (EPO) has granted a patent for Medicortex Finland Oyj, a biopharmaceutical company focusing on development of diagnostics and treatments for traumatic brain injury (TBI). The patent strengthens Medicortex's unique approach for detection of glycan-based indicators of brain trauma.
Medicortex Signs a Share Purchase Agreement (SPA) with Nosium Ab (publ) – Strengthens Path Toward Commercializing TBI Diagnostics24.11.2025 10:13:02 EET | Press release
Medicortex Finland Oyj (“Medicortex”), together with its majority shareholders, has signed a binding SPA with Nosium Ab (publ) (“Nosium”), marking a significant step toward advancing the commercialization of Medicortex’s rapid diagnostic tests for traumatic brain injury (TBI). Under the agreement, Nosium intends to acquire up to 89.9 percent of Medicortex at a valuation of EUR 1 per share. The agreement underscores strong confidence in Medicortex’s biomarker-based, non-invasive diagnostic approach for TBI.
A patent granted for Medicortex28.8.2025 12:00:00 EEST | Press release
Medicortex Finland Plc, a biopharmaceutical company focusing on development of diagnostics and drugs for mild traumatic brain injury (TBI), was granted a patent in Israel for company’s innovative method and device for non-invasive detection of TBI.
Medicortex Finland Plc signed a 1.4 million dollars research grant contract with the U.S. Department of Defense24.6.2024 11:15:00 EEST | Press release
Medicortex Finland Plc, a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI), announces that the United States Department of Defense (“DoD”) has awarded the company a research grant of about 1.4 million dollars for its project plan to develop a rapid test for detection of mild traumatic brain injury (TBI) and concussion using saliva.
Medicortex Finland Plc appointing new members for the Board of Directors3.5.2024 09:51:16 EEST | Press release
Medicortex Finland Plc, a biotechnology company located in Turku, Finland, with a proprietary biomarker technology for detection of traumatic brain injury (TBI), announces appointment of Nils Grönberg and Ville Ranta-Panula (MSc, MBA) as new members in company’s Board of Directors. Grönberg and Ranta-Panula supplement the team of scientists and clinicians with their diverse expertise in business development and management, among other skills.